Published in Biotech Business Week, January 21st, 2008
"A total of 30 healthy female subjects with a mean +/- SD age of 23.6 +/- 2.3 years and a mean body mass index of 20.5 +/- 1.7 kg/m(2) were assigned to 3 groups of 10 each in a double-blind manner, including group 1-placebo, group 2-4 mg tolterodine extended release and group 3-8 mg tolterodine extended release. The investigation was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.